Gilead Sciences (NASDAQ:GILD) CEO Sells $17,346,000.00 in Stock

Gilead Sciences, Inc. (NASDAQ:GILD) CEO Daniel Patrick O’day sold 115,640 shares of the business’s stock in a transaction dated Thursday, February 5th. The stock was sold at an average price of $150.00, for a total value of $17,346,000.00. Following the transaction, the chief executive officer owned 613,912 shares in the company, valued at approximately $92,086,800. This represents a 15.85% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Daniel Patrick O’day also recently made the following trade(s):

• On Wednesday, January 28th, Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock. The stock was sold at an average price of $139.89, for a total value of $1,398,900.00.
• On Friday, January 23rd, Daniel Patrick O’day sold 115,640 shares of Gilead Sciences stock. The shares were sold at an average price of $135.00, for a total transaction of $15,611,400.00.
• On Monday, December 29th, Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock. The shares were sold at an average price of $124.83, for a total transaction of $1,248,300.00.
• On Friday, November 28th, Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock. The shares were sold at an average price of $126.54, for a total transaction of $1,265,400.00.

Gilead Sciences Stock Up 2.1%

Shares of Gilead Sciences stock traded up $3.13 during trading hours on Friday, hitting $152.50. 8,509,218 shares of the company’s stock traded hands, compared to its average volume of 7,754,722. The stock has a 50 day simple moving average of $126.84 and a 200-day simple moving average of $120.60. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. The company has a market cap of $189.20 billion, a PE ratio of 23.64, a PEG ratio of 0.77 and a beta of 0.36. Gilead Sciences, Inc. has a twelve month low of $93.37 and a twelve month high of $153.13.

Institutional Trading of Gilead Sciences

A number of large investors have recently modified their holdings of GILD. GoalVest Advisory LLC grew its position in Gilead Sciences by 7,566.7% in the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 227 shares during the last quarter. Corundum Trust Company INC acquired a new position in Gilead Sciences during the 3rd quarter worth $26,000. Harbor Asset Planning Inc. acquired a new position in Gilead Sciences during the 2nd quarter worth $27,000. Ares Financial Consulting LLC bought a new position in shares of Gilead Sciences in the fourth quarter worth $28,000. Finally, Financial Consulate Inc. increased its holdings in shares of Gilead Sciences by 85.8% during the fourth quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 109 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on GILD. BMO Capital Markets raised their price target on shares of Gilead Sciences from $135.00 to $150.00 and gave the stock an “outperform” rating in a research report on Monday, January 26th. Leerink Partners boosted their target price on shares of Gilead Sciences from $114.00 to $146.00 and gave the stock an “outperform” rating in a research report on Friday, January 30th. Morgan Stanley reduced their price target on shares of Gilead Sciences from $151.00 to $150.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 13th. Citigroup lifted their price target on Gilead Sciences from $140.00 to $156.00 and gave the stock a “buy” rating in a research note on Tuesday, January 27th. Finally, Sanford C. Bernstein set a $135.00 price objective on Gilead Sciences and gave the company an “outperform” rating in a research note on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $136.73.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.